Suppr超能文献

正常成年人静脉注射头孢曲松的药代动力学特征。

Pharmacokinetic characteristics of intravenous ceftriaxone in normal adults.

作者信息

Pollock A A, Tee P E, Patel I H, Spicehandler J, Simberkoff M S, Rahal J J

出版信息

Antimicrob Agents Chemother. 1982 Nov;22(5):816-23. doi: 10.1128/AAC.22.5.816.

Abstract

The multiple-dose pharmacokinetics and tolerance of intravenous ceftriaxone were investigated in 44 adults with normal renal function. Doses of 0.5, 1.0, and 2.0 g every 12 h and 2 g every 24 h were administered intravenously at a constant rate over 30 min. Plasma and urine samples were collected after the first (day 1) and last (day 4) dose and assayed for ceftriaxone by high-pressure liquid chromatography. Considering all four doses, mean peak plasma concentrations ranged from 79 to 255 micrograms/ml on day 1 and from 101 to 280 micrograms/ml on day 4. Trough concentrations at 12 h on day 1 were 15 to 45 micrograms/ml and 20 to 59 micrograms/ml on day 4. After a dose regimen of 2 g every 24 h, trough levels were still in the clinically therapeutic range (13 to 15 microgram/ml). The mean beta-phase t1/2 was markedly long (6.3 to 6.9 h) and was independent of dose. The fraction of dose excreted unchanged in the urine (0.33 to 0.44) indicated a substantial nonrenal mechanism of elimination. The plasma clearance ranged between 1,002 and 1,449 ml/h, and renal clearance ranged from 353 to 529 ml/h. The apparent volume of distribution varied from 9.2 to 13.5 liters. The dose-related increases in calculated Vd and Clp could be attributed to concentration-dependent plasma protein binding because of a larger free fraction of drug at higher concentrations. The drug was well tolerated, and no significant clinical or laboratory abnormalities were noted.

摘要

在44名肾功能正常的成年人中研究了静脉注射头孢曲松的多剂量药代动力学和耐受性。每12小时分别静脉注射0.5克、1.0克和2.0克剂量,以及每24小时静脉注射2克剂量,均以恒定速率在30分钟内输注。在首次(第1天)和末次(第4天)给药后采集血浆和尿液样本,采用高压液相色谱法测定头孢曲松含量。综合考虑所有四种剂量,第1天的平均血浆峰浓度范围为79至255微克/毫升,第4天为101至280微克/毫升。第1天12小时的谷浓度为15至45微克/毫升,第4天为20至59微克/毫升。在每24小时2克的给药方案后,谷浓度仍处于临床治疗范围内(13至15微克/毫升)。平均β相半衰期明显较长(6.3至6.9小时),且与剂量无关。经尿液以原形排泄的剂量分数(0.33至0.44)表明存在大量非肾排泄机制。血浆清除率范围为1002至1449毫升/小时,肾清除率范围为353至529毫升/小时。表观分布容积为9.2至13.5升。计算得出的Vd和Clp与剂量相关的增加可能归因于浓度依赖性血浆蛋白结合,因为在较高浓度下药物的游离分数更大。该药物耐受性良好,未观察到明显的临床或实验室异常。

相似文献

1
Pharmacokinetic characteristics of intravenous ceftriaxone in normal adults.
Antimicrob Agents Chemother. 1982 Nov;22(5):816-23. doi: 10.1128/AAC.22.5.816.
2
Ceftriaxone pharmacokinetics in patients with various degrees of renal impairment.
Antimicrob Agents Chemother. 1984 Apr;25(4):438-42. doi: 10.1128/AAC.25.4.438.
3
Pharmacokinetics of ceftriaxone in humans.
Antimicrob Agents Chemother. 1981 Nov;20(5):634-41. doi: 10.1128/AAC.20.5.634.
4
Age and ceftriaxone kinetics.
Clin Pharmacol Ther. 1984 Jan;35(1):19-25. doi: 10.1038/clpt.1984.3.
5
Difference in blister fluid penetration after single and multiple doses of ceftriaxone.
Antimicrob Agents Chemother. 1985 Jul;28(1):123-7. doi: 10.1128/AAC.28.1.123.
8
Single-dose pharmacokinetics of ceftriaxone in healthy Chinese adults.
Antimicrob Agents Chemother. 1985 Feb;27(2):192-6. doi: 10.1128/AAC.27.2.192.
10
Pharmacokinetics of ceftriaxone following intravenous administration of a 3 g dose.
Eur J Clin Pharmacol. 1982;22(1):71-5. doi: 10.1007/BF00606428.

引用本文的文献

1
Comparison of ceftriaxone versus ceftaroline in combination with ampicillin or penicillin against .
Microbiol Spectr. 2025 Jun 3;13(6):e0271824. doi: 10.1128/spectrum.02718-24. Epub 2025 May 15.
2
Interaction of Cephalosporins with Human Serum Albumin: A Structural Study.
J Med Chem. 2024 Aug 22;67(16):14175-14183. doi: 10.1021/acs.jmedchem.4c00983. Epub 2024 Jul 31.
3
Ceftriaxone-induced encephalopathy in a patient with a normal renal function.
BMJ Case Rep. 2024 Jan 11;17(1):e256934. doi: 10.1136/bcr-2023-256934.
6
Penicillin-Susceptible Meningitis in Adults: Does the Ceftriaxone Dosing Matter?
Antibiotics (Basel). 2023 May 9;12(5):878. doi: 10.3390/antibiotics12050878.
7
Three-day ceftriaxone versus longer durations of therapy for inpatient treatment of uncomplicated urinary tract infection.
Antimicrob Steward Healthc Epidemiol. 2022 Oct 21;2(1):e171. doi: 10.1017/ash.2022.317. eCollection 2022.
8
Meropenem plus Ceftaroline Is Active against Enterococcus faecalis in an Pharmacodynamic Model Using Humanized Dosing Simulations.
Antimicrob Agents Chemother. 2022 Oct 18;66(10):e0042622. doi: 10.1128/aac.00426-22. Epub 2022 Sep 26.
9
Encephalopathy induced by high levels of ceftriaxone in the blood and cerebrospinal fluid.
IDCases. 2022 Jul 26;29:e01581. doi: 10.1016/j.idcr.2022.e01581. eCollection 2022.
10
Penicillin plus Ceftriaxone versus Ampicillin plus Ceftriaxone Synergistic Potential against Clinical Enterococcus faecalis Blood Isolates.
Microbiol Spectr. 2022 Aug 31;10(4):e0062122. doi: 10.1128/spectrum.00621-22. Epub 2022 Jun 15.

本文引用的文献

1
Pharmacokinetics of Ro 13-9904, a broad-spectrum cephalosporin.
Antimicrob Agents Chemother. 1980 Aug;18(2):240-2. doi: 10.1128/AAC.18.2.240.
2
Multiple intravenous dose pharmacokinetics of ceftriaxone in man.
Chemotherapy. 1981;27 Suppl 1:47-56. doi: 10.1159/000238029.
4
Ro 13-9904, a long-acting broad-spectrum cephalosporin: in vitro and in vivo studies.
Antimicrob Agents Chemother. 1980 Dec;18(6):913-21. doi: 10.1128/AAC.18.6.913.
5
In vitro antibacterial activity and susceptibility of the cephalosporin Ro 13-9904 to beta-lactamases.
Antimicrob Agents Chemother. 1980 Aug;18(2):292-8. doi: 10.1128/AAC.18.2.292.
6
Ro 13-9904/001, a novel potent and long-acting parenteral cephalosporin.
J Antibiot (Tokyo). 1980 Jul;33(7):783-6. doi: 10.7164/antibiotics.33.783.
7
In vitro activity of Ro 13-9904, a new beta-lactamase-stable cephalosporin.
Antimicrob Agents Chemother. 1981 Feb;19(2):222-5. doi: 10.1128/AAC.19.2.222.
8
Comparative multiple-dose pharmacokinetics of cefotaxime, moxalactam, and ceftazidime.
Antimicrob Agents Chemother. 1981 Nov;20(5):567-75. doi: 10.1128/AAC.20.5.567.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验